<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39340367</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2567</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Immunology</Title><ISOAbbreviation>Immunology</ISOAbbreviation></Journal><ArticleTitle>RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.13861</ELocationID><Abstract><AbstractText>The remarkable success of mRNA-based coronavirus 2019 (COVID-19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA-based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA-based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jingsheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaoyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haoran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peiyu</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kezhong</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1173-2288</Identifier><AffiliationInfo><Affiliation>Department of Oncology Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Mantang</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0419-9139</Identifier><AffiliationInfo><Affiliation>Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82173386</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant><Grant><GrantID>20230484314</GrantID><Agency>Beijing Nova Program</Agency><Country /></Grant><Grant><GrantID>2021RU002</GrantID><Agency>Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer</Agency><Country /></Grant><Grant><GrantID>2023YFF0723500</GrantID><Agency>National Key R&amp;D Program of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunology</MedlineTA><NlmUniqueID>0374672</NlmUniqueID><ISSNLinking>0019-2805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">in vivo CAR therapy</Keyword><Keyword MajorTopicYN="N">nanocarriers</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>8</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340367</ArticleId><ArticleId IdType="doi">10.1111/imm.13861</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hong MH, Clubb JD, Chen YY. Engineering CAR‐T cells for next‐generation cancer therapy. Cancer Cell. 2020;38(4):473–488.</Citation></Reference><Reference><Citation>Labanieh L, Majzner RG, Mackall CL. Programming CAR‐T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377–391.</Citation></Reference><Reference><Citation>Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev. 2014;257(1):250–263.</Citation></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T‐Cell therapy in refractory large B‐cell lymphoma. New Engl J Med. 2017;377(26):2531–2544.</Citation></Reference><Reference><Citation>Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B‐cell lymphoblastic leukemia. New Engl J Med. 2018;378(5):439–448.</Citation></Reference><Reference><Citation>Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE‐X19 for relapsed or refractory adult B‐cell acute lymphoblastic leukaemia: phase 2 results of the single‐arm, open‐label, multicentre ZUMA‐3 study. Lancet. 2021;398(10299):491–502.</Citation></Reference><Reference><Citation>Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE‐X19 anti‐CD19 CAR T‐cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA‐3 phase 1 results. Blood. 2021;138(1):11–22.</Citation></Reference><Reference><Citation>Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B‐cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.</Citation></Reference><Reference><Citation>Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl J Med. 2021;384(8):705–716.</Citation></Reference><Reference><Citation>Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open‐label study of LCAR‐B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.</Citation></Reference><Reference><Citation>Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four‐year follow‐up of LCAR‐B38M in relapsed or refractory multiple myeloma: a phase 1, single‐arm, open‐label, multicenter study in China (LEGEND‐2). J Hematol Oncol. 2022;15(1):86.</Citation></Reference><Reference><Citation>Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, et al. Recent advances in CAR‐based solid tumor immunotherapy. Cells. 2023;12(12):1606.</Citation></Reference><Reference><Citation>Sterner RC, Sterner RM. CAR‐T cell therapy: current limitations and potential strategies. Blood. Cancer J. 2021;11(4):69.</Citation></Reference><Reference><Citation>Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195.</Citation></Reference><Reference><Citation>Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T‐cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.</Citation></Reference><Reference><Citation>Juluri KR, Wu QV, Voutsinas J, Hou J, Hirayama AV, Mullane E, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T‐cell therapy. Blood Adv. 2022;6(7):2055–2068.</Citation></Reference><Reference><Citation>Perry C, Rayat ACME. Lentiviral vector bioprocessing. Viruses. 2021;13:2.</Citation></Reference><Reference><Citation>Gatti A, Morlacchi S, Mingotto F, Terreni P, Avigni R, Ferrazzano A, et al. Optimization of lentiviral vector mediated transduction of T cells for clinical use. Human Gene Therapy. 2022;33(23‐24):A113–A.</Citation></Reference><Reference><Citation>Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–288.</Citation></Reference><Reference><Citation>Allen ES, Stroncek DF, Ren JQ, Eder F, West KA, Fry TJ, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133–1141.</Citation></Reference><Reference><Citation>Milone MC, Levine BL. Powered and controlled T‐cell production. Nature Biomed Eng. 2018;2(3):148–150.</Citation></Reference><Reference><Citation>Levine BL. Performance‐enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22(2):79–84.</Citation></Reference><Reference><Citation>Gee AP. GMP CAR‐T cell production. Best Pract Res Cinl Haematol. 2018;31(2):126–134.</Citation></Reference><Reference><Citation>Gomes‐Silva D, Ramos CA. Cancer immunotherapy using CAR‐T cells: from the research bench to the assembly line. Biotechnol J. 2018;13(2):1700097.</Citation></Reference><Reference><Citation>Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.</Citation></Reference><Reference><Citation>Wang XY, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015.</Citation></Reference><Reference><Citation>Parayath NN, Stephan MT. In situ programming of CAR T cells. Annu Rev Biomed Eng. 2021;23:385–405.</Citation></Reference><Reference><Citation>Makita S, Yoshimura K, Tobinai K. Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma. Cancer Sci. 2017;108(6):1109–1118.</Citation></Reference><Reference><Citation>Ting HUA, Haoquan WU, Songlin XU. Analysis of economic and social values of mRNA vaccin. Prog Pharm Sci. 2022;46(5):359–368.</Citation></Reference><Reference><Citation>Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off‐the‐shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–199.</Citation></Reference><Reference><Citation>Qasim W, Allogeneic CAR. T cell therapies for leukemia. Am J Hematol. 2019;94:S50–S54.</Citation></Reference><Reference><Citation>Muthuvel M, Srinivasan H, Louis L, Martin S. Engineering off‐the‐shelf universal CAR T cells: A silver lining in the cloud. Cytokine. 2022;156:155920.</Citation></Reference><Reference><Citation>Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, et al. Strategies to circumvent the side‐effects of immunotherapy using allogeneic CAR‐T cells and boost its efficacy: results of recent clinical trials. Front Immunol. 2021;12:780145.</Citation></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384(5):403–416.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383(27):2603–2615.</Citation></Reference><Reference><Citation>Niu H, Zhao P, Sun W. Biomaterials for chimeric antigen receptor T cell engineering. Acta Biomater. 2023;166:1–13.</Citation></Reference><Reference><Citation>Zuo YH, Zhao XP, Fan XX. Nanotechnology‐based chimeric antigen receptor T‐cell therapy in treating solid tumor. Pharmacol Res. 2022;184:106454.</Citation></Reference><Reference><Citation>Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater. 2023;35(51):e2303261.</Citation></Reference><Reference><Citation>Qin YT, Li YP, He XW, Wang X, Li WY, Zhang YK. Biomaterials promote in vivo generation and immunotherapy of CAR‐T cells. Front Immunol. 2023;14:1165576.</Citation></Reference><Reference><Citation>Kumar ARK, Shou Y, Chan B, Tay LK. Materials for improving immune cell transfection. Adv Mater. 2021;33(21):e2007421.</Citation></Reference><Reference><Citation>Granit V, Benatar M, Kurtoglu M, Miljkovic MD, Chahin N, Sahagian G, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T‐cell therapy in myasthenia gravis (MG‐001): a prospective, multicentre, open‐label, non‐randomised phase 1b/2a study. Lancet Neurol. 2023;22(7):578–590.</Citation></Reference><Reference><Citation>Breda L, Papp TE, Triebwasser MP, Yadegari A, Fedorky MT, Tanaka N, et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science. 2023;381(6656):436–443.</Citation></Reference><Reference><Citation>Zhou JE, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin‐6 knockdown in vivo. J Control Release. 2022;350:298–307.</Citation></Reference><Reference><Citation>Rurik JG, Tombacz I, Yadegari A, Mendez Fernandez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91–96.</Citation></Reference><Reference><Citation>Kheirolomoom A, Kare AJ, Ingham ES, Paulmurugan R, Robinson ER, Baikoghli M, et al. In situ T‐cell transfection by anti‐CD3‐conjugated lipid nanoparticles leads to T‐cell activation, migration, and phenotypic shift. Biomaterials. 2022;281:121339.</Citation></Reference><Reference><Citation>Soundara Rajan T, Gugliandolo A, Bramanti P, Mazzon E. In vitro‐transcribed mRNA chimeric antigen receptor T cell (IVT mRNA CAR T) therapy in hematologic and solid tumor management: a preclinical update. Int J Mol Sci. 2020;21(18):6514.</Citation></Reference><Reference><Citation>Parayath NN, Stephan SB, Koehne AL, Nelson PS, Stephan MT. In vitro‐transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat Commun. 2020;11(1):6080.</Citation></Reference><Reference><Citation>Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, et al. In situ programming of leukaemia‐specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813–820.</Citation></Reference><Reference><Citation>Stewart MP, Langer R, Jensen KF. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts. Chem Rev. 2018;118(16):7409–7531.</Citation></Reference><Reference><Citation>Raes L, De Smedt SC, Raemdonck K, Braeckmans K. Non‐viral transfection technologies for next‐generation therapeutic T cell engineering. Biotechnol Adv. 2021;49:107760.</Citation></Reference><Reference><Citation>Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non‐viral vectors for RNA delivery. J Control Release. 2022;342:241–279.</Citation></Reference><Reference><Citation>Raguram A, Banskota S, Liu DR. Therapeutic in vivo delivery of gene editing agents. Cell. 2022;185(15):2806–2827.</Citation></Reference><Reference><Citation>Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In‐vivo induced CAR‐T cell for the potential breakthrough to overcome the barriers of current CAR‐T cell therapy. Front Oncol. 2022;12:809754.</Citation></Reference><Reference><Citation>Cobb M. Who discovered messenger RNA? Curr Biol. 2015;25(13):R526–R532.</Citation></Reference><Reference><Citation>Brachet J, Huez G, Hubert E. Microinjection of rabbit hemoglobin messenger RNA into amphibian oocytes and embryos. Proc Natl Acad Sci U S A. 1973;70(2):543–547.</Citation></Reference><Reference><Citation>Krieg PA, Melton DA. Functional messenger RNAs are produced by Sp6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 1984;12(18):7057–7070.</Citation></Reference><Reference><Citation>Huang XG, Kong N, Zhang XC, Cao YH, Langer R, Tao W. The landscape of mRNA nanomedicine. Nat Med. 2022;28(11):2273–2287.</Citation></Reference><Reference><Citation>Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33(33):445–474.</Citation></Reference><Reference><Citation>Liu QF, Li JY, Zheng HJ, Yang S, Hua YZ, Huang N, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR‐T. Mol Cancer. 2023;22(1):28.</Citation></Reference><Reference><Citation>Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnol. 2020;38(8):947.</Citation></Reference><Reference><Citation>Pan K, Farrukh H, Chittepu VCSR, Xu HH, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Canc Res. 2022;41(1):119.</Citation></Reference><Reference><Citation>Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co‐delivery for in situ generation of phagocytosis‐enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718–733.</Citation></Reference><Reference><Citation>Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM. NK cell‐based immunotherapies in cancer. Immune Netw. 2020;20(2):e14.</Citation></Reference><Reference><Citation>Zhang LS, Meng Y, Feng XM, Han ZC. CAR‐NK cells for cancer immunotherapy: from bench to bedside. Biomark Res. 2022;10(1):12.</Citation></Reference><Reference><Citation>Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100.</Citation></Reference><Reference><Citation>Diwanji N, Getts D, Wang Y. In vivo programming of natural killer cells and T cells using mRNA delivered cytotoxic chimeric antigen receptors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6_Suppl):Abstract nr 1319.</Citation></Reference><Reference><Citation>Argueta S, Melber FK, Gorgievski M, Divangi N, Cochran E, Chu T, et al. In vivo immune cell programming using mRNA‐LNP chimeric antigen receptors. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6_Suppl):Abstract nr 1321.</Citation></Reference><Reference><Citation>Wang Y, Gerber M, Gorgievski M, D'Alessandro J, Diwanji N, Vale R, et al. Preclinical &amp; clinical activity of autologous mRNA engineered chimeric antigen receptor monocytes for targeted cancer immunotherapy. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84 (6_Suppl):Abstract nr 3612.</Citation></Reference><Reference><Citation>NCT05969041. Study of MT‐302 in adults with advanced or metastatic epithelial tumors (MYE symphony). ClinicalTrials.gov. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT05969041?term=MT-302&amp;draw=2&amp;rank=1 (accessed on 16 September 2023)</Citation></Reference><Reference><Citation>MYELOID Therapeutics, Inc. MT‐302 (TROP2‐FcA LNP). Available online: https://myeloidtx.com/our-pipeline/. (accessed on 16 September 2023).</Citation></Reference><Reference><Citation>Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nature Rev Drug Disc. 2019;18(3):175–196.</Citation></Reference><Reference><Citation>Billingsley MM, Singh N, Ravikumar P, Zhang R, June CH, Mitchell MJ. Ionizable lipid nanoparticle‐mediated mRNA delivery for human CAR T cell engineering. Nano Lett. 2020;20(3):1578–1589.</Citation></Reference><Reference><Citation>Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.</Citation></Reference><Reference><Citation>Smits E, Ponsaerts P, Lenjou M, Nijs G, Van Bockstaele DR, Berneman ZN, et al. RNA‐based gene transfer for adult stem cells and T cells. Leukemia. 2004;18(11):1898–1902.</Citation></Reference><Reference><Citation>Wilson E, Goswami J, Baqui AH, Doreski PA, Perez‐Marc G, Zaman K, et al. Efficacy and safety of an mRNA‐based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233–2244.</Citation></Reference><Reference><Citation>Skerritt JH, Tucek‐Szabo C, Sutton B, Nolan T. The platform technology approach to mRNA product development and regulation. Vaccines. 2024;12(5):528.</Citation></Reference><Reference><Citation>Kis Z, Kontoravdi C, Shattock R, Shah N. Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines. 2020;9(1):3.</Citation></Reference><Reference><Citation>Ting HUA, Haoquan WU, Songlin XU. Analysis of economic and social values of mRNA vaccine. Prog Pharm Sci. 2022;46(5):359–368.</Citation></Reference><Reference><Citation>CanSinoBIO. CanSinoBIO 2020 Annual Report [EB/OL]. [2022‐04‐01]. http://www.cansinotech.com.cn/html/1//184/185/204/214/list-19.html</Citation></Reference><Reference><Citation>Foster JB, Choudhari N, Perazzelli J, Storm J, Hofmann TJ, Jain P, et al. Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T‐cell response. Hum Gene Ther. 2019;30(2):168–178.</Citation></Reference><Reference><Citation>Liu X, Barrett DM, Jiang S, Fang C, Kalos M, Grupp SA, et al. Improved anti‐leukemia activities of adoptively transferred T cells expressing bispecific T‐cell engager in mice. Blood Cancer J. 2016;6(6):e430.</Citation></Reference><Reference><Citation>Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu XJ, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26–31.</Citation></Reference><Reference><Citation>Green MR, Sambrook J. How to win the battle with RNase. Cold Spring Harb Protoc. 2019;2019(2).</Citation></Reference><Reference><Citation>Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7(2):131–137.</Citation></Reference><Reference><Citation>Lee BL, Barton GM. Trafficking of endosomal toll‐like receptors. Trends Cell Biol. 2014;24(6):360–369.</Citation></Reference><Reference><Citation>Devoldere J, Dewitte H, De Smedt SC, Remaut K. Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger. Drug Discov Today. 2016;21(1):11–25.</Citation></Reference><Reference><Citation>Kormann MSD, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber‐Jonat S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011;29(2):154–157.</Citation></Reference><Reference><Citation>Karikó K, Muramatsu H, Keller JM, Weissman D. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine‐containing mRNA encoding erythropoietin. Mol Ther. 2012;20(5):948–953.</Citation></Reference><Reference><Citation>Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.</Citation></Reference><Reference><Citation>Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015;21(2):172–179.</Citation></Reference><Reference><Citation>Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185(13):2390.</Citation></Reference><Reference><Citation>Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205–211.</Citation></Reference><Reference><Citation>Harland R, Misher L. Stability of RNA in developing Xenopus embryos and identification of a destabilizing sequence in TFIIIA messenger RNA. Development. 1988;102(4):837–852.</Citation></Reference><Reference><Citation>Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023;41(2):262–272.</Citation></Reference><Reference><Citation>Lei M, Zheng G, Ning Q, Zheng J, Dong D. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.</Citation></Reference><Reference><Citation>Dhamija S, Menon MB. Non‐coding transcript variants of protein‐coding genes—what are they good for? RNA Biol. 2018;15(8):1025–1031.</Citation></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9(1):2629.</Citation></Reference><Reference><Citation>Pamudurti NR, Bartok O, Jens M, Ashwal‐Fluss R, Stottmeister C, Ruhe L, et al. Translation of circRNAs. Mol Cell. 2017;66(1):9–21 e7.</Citation></Reference><Reference><Citation>Muller S, Appel B. In vitro circularization of RNA. RNA Biol. 2017;14(8):1018–1027.</Citation></Reference><Reference><Citation>Obi P, Chen YG. The design and synthesis of circular RNAs. Methods. 2021;196:85–103.</Citation></Reference><Reference><Citation>Beaudry D, Perreault JP. An efficient strategy for the synthesis of circular RNA molecules. Nucleic Acids Res. 1995;23(15):3064–3066.</Citation></Reference><Reference><Citation>Moore MJ. Joining RNA molecules with T4 DNA ligase. Methods Mol Biol. 1999;118:11–19.</Citation></Reference><Reference><Citation>Puttaraju M, Been MD. Group I permuted intron‐exon (PIE) sequences self‐splice to produce circular exons. Nucleic Acids Res. 1992;20(20):5357–5364.</Citation></Reference><Reference><Citation>Jarrell KA. Inverse splicing of a group II intron. Proc Natl Acad Sci U S A. 1993;90(18):8624–8627.</Citation></Reference><Reference><Citation>Beckert B, Masquida B. Synthesis of RNA by in vitro transcription. Methods Mol Biol. 2011;703:29–41.</Citation></Reference><Reference><Citation>Mabry R, Becker A, Wesselhoeft A, Horhata A, Emmanuel A, Lee T, et al. In situ CAR therapy using oRNA™ lipid nanoparticles regresses tumors in mice. Regular and Young Investigator Award Abstracts 2022. p. A1265‐A.</Citation></Reference><Reference><Citation>Chen CK, Cheng R, Demeter J, Chen J, Weingarten‐Gabbay S, Jiang L, et al. Structured elements drive extensive circular RNA translation. Mol Cell. 2021;81(20):4300–4318.e13.</Citation></Reference><Reference><Citation>Liu CX, Guo SK, Nan F, Xu YF, Yang L, Chen LL. RNA circles with minimized immunogenicity as potent PKR inhibitors. Mol Cell. 2022;82(2):420–434.e6.</Citation></Reference><Reference><Citation>Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside‐modified, protein‐encoding mRNA. Nucleic Acids Res. 2011;39(21):e142.</Citation></Reference><Reference><Citation>Qiu Z, Hou Q, Zhao Y, Zhu J, Zhai M, Li D, et al. Clean‐PIE: a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression. bioRxiv. June 22, 2022. https://doi.org/10.1101/2022.06.20.496777</Citation></Reference><Reference><Citation>Collins J, Hohn B. Cosmids: a type of plasmid gene‐cloning vector that is packageable invitro in bacteriophage lambda‐heads. Proc Natl Acad Sci U S A. 1978;75(9):4242–4246.</Citation></Reference><Reference><Citation>Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346–358.</Citation></Reference><Reference><Citation>Kouprina N, Larionov V. Human artificial chromosomes or HAC‐based gene delivery vectors for biomedicine and biotechnology. Mol Ther. 2014;22:S36–S.</Citation></Reference><Reference><Citation>Lederberg J. Cell genetics and hereditary symbiosis. Phys Rev. 1952;32(4):403–430.</Citation></Reference><Reference><Citation>Huang X, Guo HF, Kang J, Choi S, Zhou TC, Tammana S, et al. Sleeping beauty transposon‐mediated engineering of human primary T cells for therapy of CD19(+) lymphoid malignancies. Mol Ther. 2008;16(3):580–589.</Citation></Reference><Reference><Citation>Hudecek M, Izsvak Z, Johnen S, Renner M, Thumann G, Ivics Z. Going non‐viral: the sleeping beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol. 2017;52(4):355–380.</Citation></Reference><Reference><Citation>Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, et al. Phase I trials using sleeping beauty to generate CD19‐specific CAR T cells. J Clin Invest. 2016;126(9):3363–3376.</Citation></Reference><Reference><Citation>Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T‐cell engineering using non‐viral sleeping beauty transposition from minicircle vectors. Leukemia. 2017;31(1):186–194.</Citation></Reference><Reference><Citation>Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex‐mediated in vivo programming to chimeric antigen receptor‐M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):e2103258.</Citation></Reference><Reference><Citation>CAR T‐cell therapy: understanding the warning and the risks. Cancer Today. 2024 [Cited 2024 June 3]. Available from: https://www.cancertodaymag.org/cancer‐talk/car‐t‐cell‐therapy‐understanding‐the‐warning‐and‐the‐risks/</Citation></Reference><Reference><Citation>Weng YH, Li CH, Yang TR, Hu B, Zhang MJ, Guo S, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.</Citation></Reference><Reference><Citation>Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.</Citation></Reference><Reference><Citation>Stewart MP, Sharei A, Ding X, Sahay G, Langer R, Jensen KF. In vitro and ex vivo strategies for intracellular delivery. Nature. 2016;538(7624):183–192.</Citation></Reference><Reference><Citation>Yang ZG, Shi JF, Xie J, Wang YF, Sun JY, Liu TZ, et al. Large‐scale generation of functional mRNA‐encapsulating exosomes via cellular nanoporation. Nat Biomed Eng. 2020;4(1):69–83.</Citation></Reference><Reference><Citation>Lei PY, Yu HY, Ma JH, Du J, Fang YM, Yang QS, et al. Cell membrane nanomaterials composed of phospholipids and glycoproteins for drug delivery in inflammatory bowel disease: a review. Int J Biol Macromol. 2023;249:126000.</Citation></Reference><Reference><Citation>Li Y, Ma XT, Yue YL, Zhang KY, Cheng KM, Feng QQ, et al. Rapid surface display of mRNA antigens by bacteria‐derived outer membrane vesicles for a personalized tumor vaccine. Adv Mater. 2022;34(20):e2109984.</Citation></Reference><Reference><Citation>Baldassari S, Balboni A, Drava G, Donghia D, Canepa P, Ailuno G, et al. Phytochemicals and cancer treatment: cell‐derived and biomimetic vesicles as promising carriers. Pharmaceutics. 2023;15(5):1445.</Citation></Reference><Reference><Citation>Goldberg MS. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19(10):587–602.</Citation></Reference><Reference><Citation>Mukalel AJ, Riley RS, Zhang R, Mitchell MJ. Nanoparticles for nucleic acid delivery: applications in cancer immunotherapy. Cancer Lett. 2019;458:102–112.</Citation></Reference><Reference><Citation>Li T, Luo R, Su L, Lv F, Mei L, Yu Y. Advanced materials and delivery systems for enhancement of chimeric antigen receptor cells. Small Methods. 2023;7(11):e2300880.</Citation></Reference><Reference><Citation>Mabry R, Becker A, Wesselhoeft A, Horhata A, Emmanuel AO, Lee T et al.1222 In situ CAR therapy using oRNA™ lipid nanoparticles regresses tumors in mice. J Immunother Cancer. 2022; 10: A1265‐A1265.</Citation></Reference><Reference><Citation>Bozza M, De Roia A, Correia MP, Berger A, Tuch A, Schmidt A, et al. A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci Adv. 2021;7(16):eabf1333.</Citation></Reference><Reference><Citation>Zhao X, Chen J, Qiu M, Li Y, Glass Z, Xu Q. Imidazole‐based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes. Angew Chem Int Ed Engl. 2020;59(45):20083–20089.</Citation></Reference><Reference><Citation>Tenchov R, Bird R, Curtze AE, Zhou QQ. Lipid nanoparticles‐from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015.</Citation></Reference><Reference><Citation>Zhang C, Ma YF, Zhang JJ, Kuo JCT, Zhang ZK, Xie HT, et al. Modification of lipid‐based nanoparticles: An efficient delivery system for nucleic acid‐based immunotherapy. Molecules. 2022;27(6):1943.</Citation></Reference><Reference><Citation>Zhong H, Chan G, Hu YJ, Hu H, Ouyang DF. A comprehensive map of FDA‐approved pharmaceutical products. Pharmaceutics. 2018;10(4):263.</Citation></Reference><Reference><Citation>Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid‐based drugs. Nature Nanotechnol. 2019;14(12):1084–1087.</Citation></Reference><Reference><Citation>Chen HR, Yao HB, Chi JX, Li CW, Liu YL, Yang JY, et al. Engineered exosomes as drug and RNA co‐delivery system: new hope for enhanced therapeutics? Front Bioeng Biotech. 2023;11:1254356.</Citation></Reference><Reference><Citation>Jia Y, Wang X, Li L, Li F, Zhang J, Liang XJ. Lipid nanoparticles optimized for targeting and release of nucleic acid. Adv Mater. 2023;36(4):e2305300.</Citation></Reference><Reference><Citation>Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv Drug Deliver Rev. 2020;154:37–63.</Citation></Reference><Reference><Citation>Kim J, Eygeris Y, Gupta M, Sahay G. Self‐assembled mRNA vaccines. Adv Drug Deliver Rev. 2021;170:83–112.</Citation></Reference><Reference><Citation>Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.</Citation></Reference><Reference><Citation>Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliver Rev. 2021;176:113851.</Citation></Reference><Reference><Citation>Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP, et al. Naturally‐occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nature Commun. 2020;11(1):3435.</Citation></Reference><Reference><Citation>Patel SK, Billingsley MM, Frazee C, Han XX, Swingle KL, Qin JY, et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J Control Release. 2022;347:521–532.</Citation></Reference><Reference><Citation>Xu XY, Ho W, Zhang XQ, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med. 2015;21(4):223–232.</Citation></Reference><Reference><Citation>Suk JS, Xu QG, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle‐based drug and gene delivery. Adv Drug Deliver Rev. 2016;99:28–51.</Citation></Reference><Reference><Citation>Fang Y, Xue JX, Gao S, Lu AQ, Yang DJ, Jiang H, et al. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv. 2017;24(2):22–32.</Citation></Reference><Reference><Citation>Mui BL, Tam YK, Jayaraman M, Ansell SM, Du XY, Tam YYC, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucl Acids. 2013;3435(12):e139.</Citation></Reference><Reference><Citation>Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017;17(3):1326–1335.</Citation></Reference><Reference><Citation>Bangham A. The 1st description of liposomes—a citation classic commentary on diffusion of univalent ions across the Lamellae of Swollen Phospholipids by Bangham, A.D., Standish,M.M., and Watkins, J.C. Cc/Life Sci. 1989(13): 14.</Citation></Reference><Reference><Citation>Gouda A, Sakr OS, Nasr M, Sammour O. Ethanol injection technique for liposomes formulation: An insight into development, influencing factors, challenges and applications. J Drug Deliv Sci Tec. 2021;61:102174.</Citation></Reference><Reference><Citation>Pidgeon C, Mcneely S, Schmidt T, Johnson JE. Multilayered vesicles prepared by reverse‐phase evaporation: liposome structure and optimum solute entrapment. Biochemistry. 1987;26(1):17–29.</Citation></Reference><Reference><Citation>Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle‐based RNA delivery. J Control Release. 2022;344:80–96.</Citation></Reference><Reference><Citation>Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial delivery systems for mRNA vaccines. Vaccines. 2021;9(1):65.</Citation></Reference><Reference><Citation>Sakurai Y, Abe N, Yoshikawa K, Oyama R, Ogasawara S, Murata T, et al. Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti‐podoplanin antibody. J Control Release. 2022;349:379–387.</Citation></Reference><Reference><Citation>Herrera‐Barrera M, Ryals RC, Gautam M, Jozic A, Landry M, Korzun T, et al. Peptide‐guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates. Sci Adv. 2023;9(2):eadd4623.</Citation></Reference><Reference><Citation>Fidan Y, Muçaj S, Timur SS, Gürsoy RN. Recent advances in liposome‐based targeted cancer therapy. J Liposome Res. 2023;34(2):316–334.</Citation></Reference><Reference><Citation>Rai R, Alwani S, Badea I. Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Polymers. 2019;11(4):745.</Citation></Reference><Reference><Citation>Harada‐Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K. Polyion complex micelles as vectors in gene therapy—pharmacokinetics and in vivo gene transfer. Gene Ther. 2002;9(6):407–414.</Citation></Reference><Reference><Citation>Hu Y, Xu BH, Ji QX, Shou D, Sun XY, Xu JJ, et al. A mannosylated cell‐penetrating peptide‐graft‐polyethylenimine as a gene delivery vector. Biomaterials. 2014;35(13):4236–4246.</Citation></Reference><Reference><Citation>Xie FJ, Li RX, Shu WK, Zhao L, Wan JJ. Self‐assembly of Peptide dendrimers and their bio‐applications in theranostics. Mater Today Bio. 2022;14:100239.</Citation></Reference><Reference><Citation>Ke XY, Shelton L, Hu YZ, Zhu YN, Chow E, Tang HY, et al. Surface‐functionalized pegylated nanoparticles deliver messenger RNA to pulmonary immune cells. ACS Appl Mater Inter. 2020;12(32):35835–35844.</Citation></Reference><Reference><Citation>Xiang JJ, Tang JQ, Zhu SG, Nie XM, Lu HB, Shen SR, et al. IONP‐PLL: a novel non‐viral vector for efficient gene delivery. J Gene Med. 2003;5(9):803–817.</Citation></Reference><Reference><Citation>Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non‐viral vectors for gene‐based therapy. Nat Rev Genet. 2014;15(8):541–555.</Citation></Reference><Reference><Citation>Kaczmarek JC, Patel AK, Kauffman KJ, Fenton OS, Webber MJ, Heartlein MW, et al. Polymer‐lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl. 2016;55(44):13808–13812.</Citation></Reference><Reference><Citation>Tzeng SY, Guerrero‐Cázares H, Martinez EE, Sunshine JC, Quiñones‐Hinojosa A, Green JJ. Non‐viral gene delivery nanoparticles based on poly(β‐amino esters) for treatment of glioblastoma. Biomaterials. 2011;32(23):5402–5410.</Citation></Reference><Reference><Citation>Olden BR, Cheng Y, Yu JL, Pun SH. Cationic polymers for non‐viral gene delivery to human T cells. J Control Release. 2018;282:140–147.</Citation></Reference><Reference><Citation>Michels A, Ho N, Buchholz CJ. Precision medicine: In vivo CAR therapy as a showcase for receptor‐targeted vector platforms. Mol Ther. 2022;30(7):2401–2415.</Citation></Reference><Reference><Citation>Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707–715.</Citation></Reference><Reference><Citation>Agarwalla P, Ogunnaike EA, Ahn S, Froehlich KA, Jansson A, Ligler FS, et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR‐T cells. Nat Biotechnol. 2022;40(8):1250–1258.</Citation></Reference><Reference><Citation>Chao Y, Wei T, Li Q, Liu B, Hao Y, Chen M, et al. Metformin‐containing hydrogel scaffold to augment CAR‐T therapy against post‐surgical solid tumors. Biomaterials. 2023;295:122052.</Citation></Reference><Reference><Citation>de Alwis R, Gan ES, Chen S, Leong YS, Tan HC, Zhang SL, et al. A single dose of self‐transcribing and replicating RNA‐based SARS‐CoV‐2 vaccine produces protective adaptive immunity in mice. Mol Ther. 2021;29(6):1970–1983.</Citation></Reference><Reference><Citation>Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, et al. A self‐amplifying RNA vaccine against COVID‐19 with long‐term room‐temperature stability. NPJ Vaccines. 2022;7(1):136.</Citation></Reference><Reference><Citation>Ho NT, Hughes SG, Ta VT, Phan LT, Do Q, Nguyen TV, et al. Safety, immunogenicity and efficacy of the self‐amplifying mRNA ARCT‐154 COVID‐19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials. Nat Commun. 2024;15(1):4081.</Citation></Reference><Reference><Citation>Wayne CJ, Blakney AK. Self‐amplifying RNA COVID‐19 vaccine. Cell. 2024;187(8):1822.e1.</Citation></Reference><Reference><Citation>Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, et al. CAR‐cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20.</Citation></Reference><Reference><Citation>Kiaie SH, Zolbanin NM, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, et al. Recent advances in mRNA‐LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276.</Citation></Reference><Reference><Citation>Liu X, Huang P, Yang R, Deng H. mRNA cancer vaccines: construction and boosting strategies. ACS Nano. 2023;17(20):19550–19580.</Citation></Reference><Reference><Citation>Kubiatowicz LJ, Mohapatra A, Krishnan N, Fang RH, Zhang L. mRNA nanomedicine: Design and recent applications. Exploration (Beijing). 2022; 2(6):20210217.</Citation></Reference><Reference><Citation>Hou AJ, Chen LC, Chen YY. Navigating CAR‐T cells through the solid‐tumour microenvironment. Nat Rev Drug Disc. 2021;20(7):531–550.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>